JP2022509448A5 - - Google Patents
Info
- Publication number
- JP2022509448A5 JP2022509448A5 JP2021547964A JP2021547964A JP2022509448A5 JP 2022509448 A5 JP2022509448 A5 JP 2022509448A5 JP 2021547964 A JP2021547964 A JP 2021547964A JP 2021547964 A JP2021547964 A JP 2021547964A JP 2022509448 A5 JP2022509448 A5 JP 2022509448A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- atezolizumab
- bevacizumab
- resistant
- signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024213116A JP2025060639A (ja) | 2018-10-31 | 2024-12-06 | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018206076 | 2018-10-31 | ||
| JP2018206076 | 2018-10-31 | ||
| PCT/IB2019/058848 WO2020089722A1 (en) | 2018-10-31 | 2019-10-17 | Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213116A Division JP2025060639A (ja) | 2018-10-31 | 2024-12-06 | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509448A JP2022509448A (ja) | 2022-01-20 |
| JP2022509448A5 true JP2022509448A5 (enExample) | 2024-04-22 |
Family
ID=70463563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547964A Pending JP2022509448A (ja) | 2018-10-31 | 2019-10-17 | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 |
| JP2024213116A Pending JP2025060639A (ja) | 2018-10-31 | 2024-12-06 | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213116A Pending JP2025060639A (ja) | 2018-10-31 | 2024-12-06 | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12577307B2 (enExample) |
| EP (1) | EP3873527A4 (enExample) |
| JP (2) | JP2022509448A (enExample) |
| KR (1) | KR20210084560A (enExample) |
| CN (1) | CN114340679A (enExample) |
| AU (1) | AU2019372239A1 (enExample) |
| BR (1) | BR112021008117A2 (enExample) |
| CA (1) | CA3115798A1 (enExample) |
| IL (1) | IL282654A (enExample) |
| MX (1) | MX2021004709A (enExample) |
| TW (1) | TW202031291A (enExample) |
| WO (1) | WO2020089722A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| US11407832B2 (en) | 2018-12-03 | 2022-08-09 | Immuneonco Biopharmaceuticals (Shanghai) Inc. | Recombinant protein targeting PD-L1 and VEGF |
| WO2022089377A1 (en) * | 2020-10-26 | 2022-05-05 | Taizhou Eoc Pharma Co., Ltd. | Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer |
| TW202337897A (zh) * | 2021-11-18 | 2023-10-01 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｐｄ－１抗體和抗ｖｅｇｆ－ａ抗體的藥物組合及其使用方法 |
| TW202444368A (zh) * | 2023-03-30 | 2024-11-16 | 瑞典商米迪維艾克提伯拉公司 | 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP2017507900A (ja) | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| PL3102605T3 (pl) | 2014-02-04 | 2019-06-28 | Pfizer Inc. | Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu |
| MY193229A (en) | 2015-06-16 | 2022-09-26 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
| EP3322731B1 (en) * | 2015-07-14 | 2021-01-13 | Bristol-Myers Squibb Company | Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) |
| CN106397592A (zh) | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| TW201837467A (zh) | 2017-03-01 | 2018-10-16 | 美商建南德克公司 | 用於癌症之診斷及治療方法 |
-
2019
- 2019-10-17 US US17/290,197 patent/US12577307B2/en active Active
- 2019-10-17 MX MX2021004709A patent/MX2021004709A/es unknown
- 2019-10-17 WO PCT/IB2019/058848 patent/WO2020089722A1/en not_active Ceased
- 2019-10-17 CN CN201980085794.7A patent/CN114340679A/zh active Pending
- 2019-10-17 BR BR112021008117-8A patent/BR112021008117A2/pt not_active Application Discontinuation
- 2019-10-17 AU AU2019372239A patent/AU2019372239A1/en not_active Abandoned
- 2019-10-17 CA CA3115798A patent/CA3115798A1/en active Pending
- 2019-10-17 KR KR1020217015951A patent/KR20210084560A/ko not_active Withdrawn
- 2019-10-17 EP EP19880708.3A patent/EP3873527A4/en active Pending
- 2019-10-17 JP JP2021547964A patent/JP2022509448A/ja active Pending
- 2019-10-18 TW TW108137749A patent/TW202031291A/zh unknown
-
2021
- 2021-04-26 IL IL282654A patent/IL282654A/en unknown
-
2024
- 2024-12-06 JP JP2024213116A patent/JP2025060639A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022509448A5 (enExample) | ||
| Doebele et al. | Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer | |
| Choi et al. | Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma | |
| Bose et al. | Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care | |
| Saeed et al. | The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials | |
| Dorta-Estremera et al. | Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer | |
| Fan et al. | Systemic therapy for hepatocellular carcinoma: current updates and outlook | |
| Kim et al. | A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer | |
| Rougier et al. | Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer | |
| Hosein et al. | A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer | |
| Crombet Ramos et al. | Nimotuzumab for patients with inoperable cancer of the head and neck | |
| Jensen et al. | Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer | |
| Tong et al. | Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases | |
| Soularue et al. | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study | |
| Ruzsa et al. | Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) | |
| Zhou et al. | Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis | |
| JP2016540042A5 (enExample) | ||
| MX2020006042A (es) | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. | |
| JP2016520528A5 (enExample) | ||
| JP2019532047A5 (enExample) | ||
| Lee et al. | Clinical and cost effectiveness of bevacizumab+ FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea | |
| Petrillo et al. | Biomarkers for precision treatment in gastric cancer | |
| Kirstein et al. | Sequential systemic treatment in patients with hepatocellular carcinoma | |
| Moorcraft et al. | Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? | |
| Denlinger et al. | A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers |